Skip to main content

Table 3 Base case results

From: Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan

Treatment

Total

Incremental

ICER (Cost/QALY)

Costs (Yen)

QALYs

Costs (Yen)

QALYs

 

MEPM

2,530,568.97

2.18

   

CTZ/TAZ

2,955,300.18

2.35

424,731.22

0.17

2,548,738

  1. CTZ/TAZ ceftolozane/tazobactam, MEPM Meropenem, QALYs Quality adjusted life years, ICER Incremental cost-effectiveness ratio
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us